Phase III read­outs spell dis­as­ter for Genen­tech’s lead IBD drug

Roche had big plans for etrolizum­ab. Eye­ing a hy­per-com­pet­i­tive IBD and Crohn’s mar­ket where they have not his­tor­i­cal­ly been a play­er, the com­pa­ny rolled out …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER